The proposed mechanism involving the FN1‐AKT pathway could serve as a basis for the development of targeted therapies to overcome progesterone resistance in endometriosis, which means that we can target the mesothelium to fix endometriotic progesterone resistance. This evidence concerns the gene AKT1 and endometriosis.